TempraMed Technologies Ltd, a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce a new commercial order and an extension of its distribution partnership in South Korea.

The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–based healthcare distribution company (www.mavens.kr), marks another step forward in TempraMed's growth across Asia and follows the recent granting of a South Korean patent protecting its proprietary thermal-insulation technology. Mavens brings established relationships across the South Korean healthcare ecosystem, supporting continued market expansion and access to patients and care providers nationwide.

South Korea represents one of the region's fastest-growing markets for injectable therapies, supported by a robust pharmaceutical industry. The country's pharmaceutical market is one of the largest in Asia, with revenues expected to grow significantly over the next decade.

Within this broader market, diabetes medications — including insulin and newer non-insulin injectables — show strong demand. The South Korean diabetes drugs sector alone is valued at nearly US$1 Bn and is projected to continue growing as the prevalence of diabetes rises with aging and lifestyle shifts¹.

As patients increasingly rely on temperature-sensitive therapies such as insulin, GLP-1 receptor agonists, biologics, and emergency injectables, protecting these medications from heat, cold, and environmental extremes becomes critical. Heat and cold exposure can degrade potency and jeopardize treatment effectiveness, highlighting the importance of reliable passive thermal protection in everyday life.

The extended distribution agreement strengthens TempraMed's footprint within South Korea's healthcare and retail ecosystems, enabling broader reach to pharmacies, hospitals, clinics, and patient communities. By deepening its partnership with its South Korean distributor, TempraMed aims to accelerate market penetration in the region and support people living with chronic conditions in their daily lives.

This expanded relationship builds on TempraMed's recent distribution agreements across Turkey, Israel, and Europe, reinforcing the Company's accelerating global expansion strategy.

"Our ongoing partnership with TempraMed has demonstrated the importance of practical, everyday solutions for patients using injectable medications," said Chang Gyu An, CEO, Mavens. "This expanded agreement allows us to build on existing momentum and further integrate these solutions into South Korea's healthcare and pharmacy ecosystem."

"This expanded partnership comes at a pivotal time for South Korea, where demand for injectable medications — from diabetes therapies to biologics — is rising rapidly. We look forward to fulfilling the commercial order and therefore providing our devices to the South Korean healthcare market," said Ron Nagar, CEO, TempraMed. "With our newly granted patent, an even stronger local presence, and the recent launch of our VIVI Cap Smart device, we are better positioned than ever to ensure that patients and healthcare providers have access to reliable temperature-protection solutions that safeguard medication quality and support better health outcomes. We are encouraged by our continued, strong relationship with Mavens, and are excited for further expansion opportunities."